Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models

Radiotherapy and Oncology

Volumn 106, Issue 3, 2013, Pages 383-389

  Stegeman, Hanneke ^a   Kaanders, Johannes H ^a   Van Der Kogel, Albert J ^a   Iida, Mari ^b   Wheeler, Deric L ^b   Span, Paul N ^a   Bussink, Johan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

EGFR inhibition; Head and neck cancer; Radiotherapy; Tumor microenvironment; Tyrosine kinase receptors

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; HER3 PROTEIN; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIOSENSITIVITY; TREATMENT RESPONSE; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL PROLIFERATION; CHEMORADIOTHERAPY; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, INBRED BALB C; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876146036     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.02.001     Document Type: Article

References (33)

1. H.P. Rodemann, K. Dittmann, and M. Toulany Radiation-induced EGFR-signaling and control of DNA-damage repair Int J Radiat Biol 83 2007 781 791
2. J. Bussink, A.J. van der Kogel, and J.H. Kaanders Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer Lancet Oncol 9 2008 288 296
3. K.K. Ang, B.A. Berkey, and X. Tu Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma Cancer Res 62 2002 7350 7356
4. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
5. D.L. Wheeler, E.F. Dunn, and P.M. Harari Understanding resistance to EGFR inhibitors-impact on future treatment strategies Nat Rev Clin Oncol 7 2010 493 507
6. J. Bussink, J.H. van der Kaanders, and A.J. Kogel Microenvironmental transformations by VEGF- and EGF-receptor inhibition and potential implications for responsiveness to radiotherapy Radiother Oncol 82 2007 10 17
7. J. Jeuken, A. Sijben, and C. Alenda Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics Brain Pathol 19 2009 661 671
8. N. Knijn, L.J. Mekenkamp, and M. Klomp KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients Br J Cancer 104 2011 1020 1026
9. T. Andersson, L. Alfredsson, H. Kallberg, S. Zdravkovic, and A. Ahlbom Calculating measures of biological interaction Eur J Epidemiol 20 2005 575 579
10. M. Krause, G. Ostermann, and C. Petersen Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation Radiother Oncol 76 2005 162 167
11. C.J. Allegra, J.M. Jessup, and M.R. Somerfield American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy J Clin Oncol 27 2009 2091 2096
12. J.C. Sok, F.M. Coppelli, and S.M. Thomas Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting Clin Cancer Res 12 2006 5064 5073
13. S.A. Weppler, Y. Li, and L. Dubois Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance Radiother Oncol 83 2007 333 339
14. B.C. Fuchs, T. Fujii, and J.D. Dorfman Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells Cancer Res 68 2008 2391 2399
15. J. Theys, B. Jutten, and R. Habets E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells Radiother Oncol 99 2011 392 397
16. G.O. Janssens, S.E. Rademakers, and C.H. Terhaard Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial J Clin Oncol 30 2012 1777 1783
17. J.H. Kaanders, K.I. Wijffels, and H.A. Marres Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer Cancer Res 62 2002 7066 7074
18. D. Rischin, R.J. Hicks, and R. Fisher Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02 J Clin Oncol 24 2006 2098 2104
19. K. Toustrup, B.S. Sorensen, and M. Nordsmark Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer Cancer Res 71 2011 5923 5931
20. A. Yaromina, H. Thames, and X. Zhou Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation Radiother Oncol 96 2010 116 122
21. A. Yaromina, D. Zips, and H.D. Thames Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies Radiother Oncol 81 2006 122 129
22. D.M. Atkinson, M.J. Clarke, and A.C. Mladek Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts Head Neck 30 2008 790 799
23. E.G. Troost, J. Bussink, A.L. Hoffmann, O.C. Boerman, W.J. Oyen, and J.H. Kaanders 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors J Nucl Med 51 2010 866 874
24. Hoeben BAW, Troost EGC, van Herpen CM, Bussink J, Oyen WJ, Kaanders JHAM. 18F-FLT PET is an early predictor of long-term outcome during (chemo)radiotherapy in head and neck carcinoma patients. J Nucl Med, in press.
25. K. Gurtner, Y. Deuse, and R. Butof Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression Radiother Oncol 99 2011 323 330
26. D.L. Wheeler, S. Huang, and T.J. Kruser Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members Oncogene 27 2008 3944 3956
27. H. Xu, L.P. Stabile, C.T. Gubish, W.E. Gooding, J.R. Grandis, and J.M. Siegfried Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells Clin Cancer Res 17 2011 4425 4438
28. A. Guo, J. Villen, and J. Kornhauser Signaling networks assembled by oncogenic EGFR and c-Met Proc Natl Acad Sci USA 105 2008 692 697
29. G. Schaefer, L. Haber, and L.M. Crocker A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies Cancer Cell 20 2011 472 486
30. J.A. Bonner, E.S. Yang, H.Q. Trummell, S. Nowsheen, C.D. Willey, and K.P. Raisch Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma Radiother Oncol 99 2011 339 343
31. S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer J Natl Cancer Inst 101 2009 1308 1324
32. F.G. Pernas, C.T. Allen, and M.E. Winters Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer Clin Cancer Res 15 2009 2361 2372
33. H. Stegeman, J.H. Kaanders, and D.L. Wheeler Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck BMC Cancer 12 2012 463